GlassScriptPhysician profile
Brian Hughes
NPI 1760621890
$4,031.26
in general payments reported to CMS, 2019-2025
22 companies · $699 in 2025
The $699 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $565 · 2022: $636 · 2023: $857 · 2024: $1,275 · 2025: $699.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,830.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,830.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $973.78 | 2021-2025 | |
| Abbvie INC. | $635.87 | 2021-2025 | |
| Amgen INC. | $378.50 | 2022-2025 | Otezla, Otezla |
| Regeneron Healthcare Solutions, INC. | $324.40 | 2021-2025 | Dupixent |
| Ucb, INC. | $224.34 | 2024-2025 | Bimzelx |
| Janssen Biotech, INC. | $213.32 | 2022-2024 | Tremfya, Stelara, Simponi Aria |
| Incyte Corporation | $181.80 | 2021-2025 | Opzelura |
| Sun Pharmaceutical Industries INC. | $181.20 | 2021-2024 | Absorica Ld, Winlevi |
| Dermavant Sciences, INC. | $140.15 | 2022-2024 | Vtama |
| Leo Pharma INC. | $123.26 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $113.11 | 2021-2025 | |
| Lilly USA, LLC | $112.16 | 2022-2024 | Olumiant, Taltz, Ebglyss |
| Pfizer INC. | $100.47 | 2021-2023 | |
| Galderma Laboratories, L.P. | $81.58 | 2022-2025 | Nemluvio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.93 | 2024-2025 | Spevigo |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $36.68 | 2023 | Xeomin |
| Sanofi-Aventis U.S. LLC | $36.24 | 2021 | |
| Orthofix Medical, INC. | $36.03 | 2023 | Trinity Elite |
| Ethicon US, LLC | $31.62 | 2025 | Vistaseal |
| Haemonetics Corporation | $24.23 | 2025 | Teg6s Hemostasis System |
| Biofrontera INC. | $23.81 | 2023 | Xepi, Bf-Rhodoled, Ameluz |
| Phadia US INC. | $16.78 | 2024 | Immunocap |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Hughes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.